Frances Luff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The value conundrum Gilead’s Frances Luff considers how updating NICE’s cost appraisal process and its take on value could secure fairer access to innovative treatments in the UK Over the last year, the COVID-19 pandemic has presented the healthcare system with an unprecedented challenge – and the life sciences industry and public sector have responded by working in close partnership to develop and provide medical and care solutions on a scale that has never been seen before. The first trials for treatments were activated within weeks of the first reported outbreak of COVID-19, and just...

PharmaTimes - April 2021 With the anchor now securely lodged in 2021, what’s on the horizon for the life sciences industry and for healthcare in the UK? Certainly for healthcare, the tide seems to be turning again. As the team at Wilmington outlines on page 16, the government is proposing some of the most important reforms for health and social care in nearly a decade, which plan a shift away from competition towards collaborative working, but also seek to hand more power to ministers to intervene in decisions on healthcare services. Elsewhere, Dr Kath MacKay looks into three areas for dev...